INS- National Institute of Health, France
Jerzy Trojan currently works in INS- National Institute of Health, France.
Strategy of immune-gene therapy based on anti-gene anti IGF-I approach (antisense/triple helix) established in the experimental treatment of murineglioma, hepatoma and teratocarcinoma has permitted to stop the development of cancer structures in tumour bearing animals. Th e eff ectiveness of anti-gene anti IGF-I therapy was evaluated in clinical treatment principally of brain malignant tumour – glioblastomamultiforme (six cases), and then in cancers of liver, colon, ovary, uterus and prostate (two cases of each). Th e glioblastomapatients treated by classical surgery followed by radiotherapy were “vaccinated” by injection of genetically modifi ed cancer cells: cultured cancer cells, originated from tumor removed during surgery, were transfected by antisense/triple helix anti IGF-I expression vectors. Th e PBL cells of treated patients have demonstrated an increasing level of T CD8+CD28+ cells with characteristic switch from CD8+11b+ to CD8+11b- aft er every of the three vaccinations. Th e minimum survival of treated glioblastomapatients was 19 months and maximum 24 months (in two cases three and four years, respectively). Other cancer patients were supervised up to 19 months. Th e described Phase I trial presents promising results - an increase in immune response goes together with life span. Th ese results have confi rmed the role of immune phenomenon present in antisense anti IGF-I strategy investigated in preclinical experiments – suppression of animal tumours treated by the same cellular gene therapy inducing T CD8+ response.
No Photos Avilable
No PDF File Avilable
No PPT File Avilable